CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to KALA

KPI-121 0.25% Ophthalmic Suspension

Phase 3
Kala Pharmaceuticals, Inc. (KALA)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Dry Eye Syndromes

View Full Landscape
Drug Information

Target Indication

Dry Eye Syndromes

Clinical Trial

NCT02813265

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.